|1.||Prostran, Milica Š: 1 article (02/2015)|
|2.||Savić Vujović, Katarina R: 1 article (02/2015)|
|3.||Srebro, Dragana P: 1 article (02/2015)|
|4.||Vučković, Sonja M: 1 article (02/2015)|
|5.||Dell, C P: 1 article (07/2000)|
|6.||Wiernicki, T R: 1 article (07/2000)|
|7.||Lodge, D: 1 article (07/2000)|
|8.||O'Neill, M J: 1 article (07/2000)|
|9.||Roman, C R: 1 article (07/2000)|
|10.||Hicks, C A: 1 article (07/2000)|
|1.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
07/21/2000 - "These results demonstrate that ARL 17477 protects against global ischaemia in gerbils and provides some reduction in infarct volume following transient middle cerebral artery occlusion in rats, indicating that nNOS inhibition may be a useful treatment of ischaemic conditions."
07/01/1996 - "ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats."
06/01/1999 - "This hyperalgesia was dose-dependently and reversibly attenuated by intrathecal administration of the nonselective NO* synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (100-800 nmol) as well as by the selective neuronal NOS inhibitor ARL 17477 (30-600 nmol). "
02/01/2015 - "Isotonic MS-induced mechanical hyperalgesia was reduced in a dose-dependent manner by co-injection of camphor, a non-selective TRPA1 antagonist (0.3, 1 and 2.5 μg/paw), MK-801, a NMDA receptor antagonist (0.001, 0.025 and 0.1 μg/paw), L-NAME, a non-selective nitric oxide (NO) synthase inhibitor (20, 50 and 100 μg/paw), ARL 17477, a selective neuronal NOS inhibitor (5.7 and 17 μg/paw), SMT, a selective inducible NOS inhibitor (1 and 2.78 μg/paw), and methylene blue, a guanylate cyclase inhibitor (5, 20 and 125 μg/paw). "
|1.||NG-Nitroarginine Methyl Ester (L-NAME)
|2.||Nitric Oxide Synthase (NO Synthase)
|3.||Dizocilpine Maleate (Dizocilpine)
|5.||Nitric Oxide (Nitrogen Monoxide)
|6.||Methylene Blue (Methylthioninium Chloride)
|7.||Guanylate Cyclase (Guanylyl Cyclase)